×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATRA – atara biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
06:00 pm
atra
Pomerantz LLP Files Class Action Litigation Against Atara Biotherapeutics, Inc. – ATRA
Neutral
Report
Pomerantz LLP Files Class Action Litigation Against Atara Biotherapeutics, Inc. – ATRA
4/24
05:24 pm
atra
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
Neutral
Report
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
4/24
03:32 pm
atra
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Low
Report
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
4/24
10:00 am
atra
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
4/24
09:00 am
atra
Lost Money on Atara Biotherapeutics, Inc. (ATRA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Low
Report
Lost Money on Atara Biotherapeutics, Inc. (ATRA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
4/24
07:00 am
atra
Pomerantz LLP Pursues Shareholder Class Action Against Atara Biotherapeutics, Inc. – ATRA
Low
Report
Pomerantz LLP Pursues Shareholder Class Action Against Atara Biotherapeutics, Inc. – ATRA
4/24
07:00 am
atra
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Low
Report
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
4/23
09:55 pm
atra
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Low
Report
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Date
Time
Symbol
Company Name
Action
%Chg
3/16/2026
04:05 pm
atra
atara biotherapeutics, inc.
MISS
Report
-10.9%
atara biotherapeutics, inc.
11/12/2025
09:00 am
atra
atara biotherapeutics, inc.
BEAT
Report
0.7%
atara biotherapeutics, inc.
5/15/2025
08:35 am
atra
atara biotherapeutics, inc.
BEAT
Report
5.4%
atara biotherapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/24
04:16 pm
atra
Form DEF 14A Atara Biotherapeutics, For: Apr 24
Neutral
Report
Form DEF 14A Atara Biotherapeutics, For: Apr 24
4/24
04:15 pm
atra
Form DEFA14A Atara Biotherapeutics,
Neutral
Report
Form DEFA14A Atara Biotherapeutics,
3/26
06:04 am
atra
Form EFFECT Atara Biotherapeutics,
Medium
Report
Form EFFECT Atara Biotherapeutics,
3/25
05:08 pm
atra
Form 424B3 Atara Biotherapeutics,
Medium
Report
Form 424B3 Atara Biotherapeutics,
3/19
04:31 pm
atra
Form 4 Atara Biotherapeutics, For: Mar 17 Filed by: Huang James
Medium
Report
Form 4 Atara Biotherapeutics, For: Mar 17 Filed by: Huang James
3/17
04:17 pm
atra
Form S-3 Atara Biotherapeutics,
Medium
Report
Form S-3 Atara Biotherapeutics,
3/16
04:20 pm
atra
Form 424B5 Atara Biotherapeutics,
High
Report
Form 424B5 Atara Biotherapeutics,
3/16
04:16 pm
atra
Form 10-K Atara Biotherapeutics, For: Dec 31
High
Report
Form 10-K Atara Biotherapeutics, For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
25.1%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
TOP News Decliners
5/9
Q1/2019 3/31/2019 EPS -1.440 ZacksConsensus -1.480 ActVsEst 0.040 - Beat
-20.6%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: